HCPLive Network

Placebo Often Effective for Treating Headache in Children

 
TUESDAY, Jan. 29 (HealthDay News) -- Placebo is often effective in treating children with headaches, and innovative strategies are needed to reduce the placebo response rate and prove drug effects in trials, according to two studies published online Jan. 28 in JAMA Pediatrics.

In the first study, Khalil El-Chammas, M.D., from the Medical College of Wisconsin in Milwaukee, and colleagues performed a meta-analysis of 21 randomized trials assessing prophylactic headache treatment to reduce the frequency or severity of headaches in children and adolescents. The researchers found that placebos were effective, while drugs, including topiramate and trazodone, showed some efficacy for episodic migraines. Other commonly used drugs were no more effective than placebo.

In the second study, Haihao Sun, M.D., Ph.D., from the U.S. Food and Drug Administration in Silver Spring, Md., and colleagues performed a systematic review and analysis of pediatric trial data submitted to the FDA on triptans, already approved for adults but which had failed to show efficacy for treatment of abortive migraines in children. The researchers observed a high placebo response, with pain relief at two hours ranging from 53.0 to 57.5 percent, which could be reduced by non-randomization of patients with an early placebo response.

"Innovative trial designs intended to reduce the placebo response rate may be necessary to demonstrate a drug effect," Sun and colleagues write.
 

Abstract - El-Chammas
Full Text (subscription or payment may be required)

Abstract - Sun
Full Text (subscription or payment may be required)
 
Editorial (subscription or payment may be required)


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Treatment with a supraorbital transcutaneous stimulator seems safe and effective for preventing migraine headaches, according to a study published online Feb. 6 in Neurology.
Although they have all participated in the development of treatment guidelines for a variety of pain conditions, 3 comprehensive pain experts openly acknowledged and discussed the practical limitations of published evidence-based recommendations during the closing session of the American Academy of Pain Medicine 2014 Annual Meeting.
The clinical challenge of accurate headache diagnosis in the office can be overcome by taking a broad view of the various diagnostic categories of headache.
Morbidly or severely obese individuals develop migraine disorders significantly more often than patients who carry less weight.
For patients who suffer from migraine with aura, provocation with natural self-reported trigger factors causes migraine in only a small subgroup, according to a study published online Jan. 23 in Neurology.
Zecuity, a sumatriptan iontophoretic single-use, battery-powered transdermal system, has been approved by the U.S. Food and Drug Administration for acute treatment of migraine with or without aura in adults.
Although many migraine sufferers can abort their headaches with over-the-counter remedies, a significant percentage of patients require prescription medication for relief.
More Reading